The Shotlee Journal
Browse Shotlee articles about Weight Management.
Showing 9 / 869 Weight Management articles
Radio host Matt Cooper reveals his journey as an early Ozempic adopter for type 2 diabetes. He defends users struggling with weight, sharing how the GLP-1 drug curbs appetite and led to gallbladder removal. Learn from his candid experiences on semaglutide benefits and challenges.
A new University of Oxford study reveals that GLP-1 users regain weight rapidly after stopping medications like Ozempic, with cardiometabolic benefits reversing within two years. This underscores the need for portion-controlled, nutrient-dense foods to maintain satiety on fewer calories. Food innovation will play a key role in supporting former users.
GLP-1 drugs are revolutionizing more than just waistlines, with nationwide usage doubling rapidly. These medications mimic the gut hormone glucagon-like peptide to signal fullness to the brain and slow gut motility. However, they often trigger GI side effects like nausea and vomiting, especially during dose changes.
A retrospective study of 250 adults found most safely used GLP-1 receptor agonists and dermatologic biologics together for 19 months. Only 19-39% of discontinuations linked to side effects, matching known individual drug profiles. Clinicians gain reassurance for patients with metabolic and immunologic needs.
Lupin has signed a licensing and supply agreement with Galenicum for injectable Semaglutide in 23 countries. Galenicum handles development and manufacturing, while Lupin manages approvals and commercialization. This boosts access to the GLP-1 drug for diabetes and obesity treatment.
A woman called Mounjaro 'magical' after dropping 3.5 stone and easing PCOS symptoms. But intense pain hospitalized her with pancreatitis linked to the drug. Now facing lifelong risks, she warns others to monitor symptoms closely.
GLP-1 receptor agonists excel in weight management and glucose control, but their effects on women's reproductive health demand attention. These drugs can restore ovulation in obese women with insulin resistance, yet they risk unplanned pregnancies and are unsafe during gestation. Consult experts before use.
Popular GLP-1 drugs are delivering unexpected savings to airlines, with $580 million in annual fuel cost reductions projected for major U.S. carriers. Analyst Sheila Kahyaoglu's research links passenger weight loss to lower operating expenses. Discover how this weight management trend reshapes aviation economics.
Doctor Karan Rajan explains why you might regain weight after quitting GLP-1 drugs: they mimic treatments for chronic conditions like high blood pressure. Obesity requires ongoing management with lifestyle factors like diet, exercise, and sleep. Not everyone needs GLP-1s forever, but stopping without changes risks relapse.
